Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
Substituted benzaldehydes have been designed to bind preferentially to the oxy conformation of human haemoglobin at a site between the amino terminal residues of the alpha-subunits. Such compounds should stabilize the oxygenated form of haemoglobin and thereby increase its oxygen affinity. The compounds produce the expected effect, left-shifting the oxygen saturation curve of dilute haemoglobin solutions and of whole blood, although the binding pattern to haemoglobin is more complex than envisaged by the design hypothesis. The predicted best compound is also a potent inhibitor, at low oxygen pressure, of the sickling of erythrocytes from patients homozygous for sickle cell disease, and may prove to be a clinically useful anti-sickling agent.
D019794:2,3-Diphosphoglycerate; D000755:Anemia, Sickle Cell / Q000097:blood*; D000986:Antisickling Agents / Q000138:chemical synthesis; D001547:Benzaldehydes / Q000138:chemical synthesis / Q000494:pharmacology*; D004163:Diphosphoglyceric Acids / Q000494:pharmacology; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D010100:Oxygen / Q000097:blood*; D013329:Structure-Activity Relationship
D000986:Antisickling Agents; D001547:Benzaldehydes; D004163:Diphosphoglyceric Acids; D006454:Hemoglobins; D019794:2,3-Diphosphoglycerate; D010100:Oxygen